SEC Form 4 · accession 0001232524-15-000017
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey K Tobias
Officer — EVP, R&D & CMO
Period of report
Feb 10, 2015
Accepted (ET)
Feb 12, 2015 · 7:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Feb 10, 2015 | M | 5,000 | $46.83 | A | 40,063 | D | |
| Ordinary SharesF3 | Feb 10, 2015 | S | 3,000 | $166.482 | D | 37,063 | D | |
| Ordinary SharesF4 | Feb 10, 2015 | S | 2,000 | $167.3361 | D | 35,063 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $46.83 | Feb 10, 2015 | M | 5,000 | D | — | Aug 8, 2022 | Ordinary Shares | 5,000 | 25,019 | D |
Explanation of responses
- F1Includes 123 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 28, 2014.
- F2The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.03 to $166.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.01 to $167.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F5As of the date of this report, the remaining ordinary shares subject to this option are vested with respect to 2,682 shares and will vest with respect to 12,805 shares in equal monthly installments from March 9, 2015 to December 9, 2015 and with respect to 9,532 shares in equal monthly installments from January 9, 2016 to August 9, 2016.